Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 17;3(5):42.
doi: 10.3892/mi.2023.102. eCollection 2023 Sep-Oct.

Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review)

Affiliations
Review

Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review)

Sara Fathallah et al. Med Int (Lond). .

Abstract

Driven by the limitations and obstacles of the available approaches and medications for multiple sclerosis (MS) that still cannot treat the disease, but only aid in accelerating the recovery from its attacks, the use of naturally occurring molecules as a potentially safe and effective treatment for MS is being explored in model organisms. MS is a devastating disease involving the brain and spinal cord, and its symptoms vary widely. Multiple molecular pathways are involved in the pathogenesis of the disease. The present review showcases the recent advancements in harnessing nature's resources to combat MS. By deciphering the molecular pathways involved in the pathogenesis of the disease, a wealth of potential therapeutic agents is uncovered that may revolutionize the treatment of MS. Thus, a new hope can be envisioned in the future, aiming at paving the way toward identifying novel safe alternatives to improve the lives of patients with MS.

Keywords: antioxidants; molecular pathways; multiple sclerosis; naturally occurring molecules; neurodegenerative diseases; therapeutic approaches.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

References

    1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler J. 2020;26:1816–1821. doi: 10.1177/1352458520970841. - DOI - PMC - PubMed
    1. Chiurchiù V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Prog Neurobiol. 2018;160:82–100. doi: 10.1016/j.pneurobio.2017.10.007. - DOI - PubMed
    1. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19:1–10. doi: 10.22074/cellj.2016.4867. - DOI - PMC - PubMed
    1. Nishanth K, Tariq E, Nzvere FP, Miqdad M, Cancarevic I. Role of smoking in the pathogenesis of multiple sclerosis: A review article. Cureus. 2020;12(e9564) doi: 10.7759/cureus.9564. - DOI - PMC - PubMed
    1. Pfeuffer S, Kerschke L, Ruck T, Rolfes L, Pawlitzki M, Albrecht P, Wiendl H, Meuth SG. Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis. Ther Adv Neurol Disord. 2021;14(1756286421997372) doi: 10.1177/1756286421997372. - DOI - PMC - PubMed

LinkOut - more resources